NO20051074L - Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi - Google Patents

Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Info

Publication number
NO20051074L
NO20051074L NO20051074A NO20051074A NO20051074L NO 20051074 L NO20051074 L NO 20051074L NO 20051074 A NO20051074 A NO 20051074A NO 20051074 A NO20051074 A NO 20051074A NO 20051074 L NO20051074 L NO 20051074L
Authority
NO
Norway
Prior art keywords
treatment
diseases
compounds
respond
antiangiogenetic
Prior art date
Application number
NO20051074A
Other languages
English (en)
Norwegian (no)
Inventor
Palle Christophersen
Bjarne H Dahl
Jens Lichtenberg
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO20051074L publication Critical patent/NO20051074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20051074A 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi NO20051074L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (1)

Publication Number Publication Date
NO20051074L true NO20051074L (no) 2005-04-29

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051074A NO20051074L (no) 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Country Status (17)

Country Link
US (1) US20060058395A1 (de)
EP (1) EP1526851B1 (de)
JP (1) JP2005537336A (de)
KR (1) KR20050026091A (de)
CN (1) CN1671378A (de)
AT (1) ATE372770T1 (de)
AU (1) AU2003260280A1 (de)
BR (1) BR0312929A (de)
CA (1) CA2493253A1 (de)
DE (1) DE60316297T2 (de)
IL (1) IL166040A0 (de)
IS (1) IS7723A (de)
MX (1) MXPA05001235A (de)
NO (1) NO20051074L (de)
NZ (1) NZ537809A (de)
PL (1) PL375318A1 (de)
WO (1) WO2004012733A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527735A (ja) * 2003-06-17 2006-12-07 ノイロサーチ アクティーゼルスカブ ジフェニル尿素誘導体、及びクロライドチャネル遮断剤としてのそれらの使用
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1853286A2 (de) * 2005-02-08 2007-11-14 BMZ Diagnosis (2004) Ltd. Zusammensetzung zur behandlung von hauterkrankungen
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
MX2007016501A (es) 2005-06-27 2008-03-06 Squibb Bristol Myers Co Antagonistas heterociclicos n-enlazados del receptor de p2y1, utiles en el tratamiento de condiciones tromboticas.
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (de) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
SI3458052T1 (sl) 2016-05-17 2020-04-30 Scandion Oncology A/S Kombinirano zdravljenje raka
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
IL132107A (en) * 1997-04-22 2004-09-27 Neurosearch As Substituted phenyl derivatives, their preparation and use
JP4607318B2 (ja) * 1997-12-22 2011-01-05 バイエル コーポレイション 対称および非対称置換ジフェニル尿素を用いるｒａｆキナーゼの阻害
CA2342626A1 (en) * 1998-10-22 2000-05-04 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
ATE543497T1 (de) * 2002-07-09 2012-02-15 Bristol Myers Squibb Co Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Also Published As

Publication number Publication date
CN1671378A (zh) 2005-09-21
EP1526851B1 (de) 2007-09-12
EP1526851A2 (de) 2005-05-04
WO2004012733A9 (en) 2005-03-10
KR20050026091A (ko) 2005-03-14
PL375318A1 (en) 2005-11-28
US20060058395A1 (en) 2006-03-16
DE60316297T2 (de) 2008-06-19
CA2493253A1 (en) 2004-02-12
JP2005537336A (ja) 2005-12-08
NZ537809A (en) 2007-05-31
MXPA05001235A (es) 2005-06-08
IL166040A0 (en) 2006-01-15
AU2003260280A1 (en) 2004-02-23
WO2004012733A2 (en) 2004-02-12
WO2004012733A3 (en) 2004-03-18
IS7723A (is) 2005-03-01
DE60316297D1 (de) 2007-10-25
BR0312929A (pt) 2005-07-12
ATE372770T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
NO20051074L (no) Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
TW200736231A (en) Substituted pyrimidines
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2004032882A3 (en) Chemical compounds
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
NO20084396L (no) Kombinasjonsterapi
EP4183806A3 (de) Glycaninteragierende verbindungen und verfahren zur verwendung
WO2004108139A3 (en) Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
EP1503757A4 (de) Tyrosinkinase-hemmer
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
ATE553122T1 (de) Antiangiogene methoden und zusammensetzungen
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
EP4413996A3 (de) Neuartige antikörper gegen faktor xi und verwendungen davon
MX2021013602A (es) Inhibidores de jak.